Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Metformin** is an orally administered small-molecule biguanide antihyperglycemic drug approved for type 2 diabetes mellitus. It lowers glucose principally by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving peripheral insulin sensitivity. In the University of Cincinnati Phase I study NCT02325401, metformin was repurposed as an investigational adjunct to concurrent cisplatin and radiation therapy for locally advanced head and neck squamous cell carcinoma. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45cc673a-e125-4d76-8013-89a089eb0ae9))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metformin (University of Cincinnati).